Prilenia: Prilenia appoints new management staff to advance company's development and commercialisation plans

Prilenia, a clinical stage biotech focusing on neurodegenerative and neurodevelopmental disorders, has announced the appointment of two new senior staff members ‒ Rob Lauzen as chief financial officer (CFO) and Jason Marks as chief legal officer (CLO). Rob Lauzen, most recently vice president of Investor Relations and head of Financial Planning & Analysis at Dyne [...] The post Prilenia appoints new management staff to advance company's development and commercialisation plans appeared first on Pharmafile.